Latest Asx Listings News

NeuRizer Ltd has completed a $200,000 private share placement, issuing over 133 million new shares to support working capital and advance its Urea Project.

Toys"R"Us ANZ has entered a strategic three-year partnership with Directed Electronics Australia to co-develop private label products and enhance marketing capabilities, marking a pivotal step in its growth strategy.

Acorn Capital Investment Fund Limited has been suspended from ASX trading due to a delayed periodic report, raising questions about its compliance and investor transparency.

James Bay Minerals has bolstered its executive team with founder Matthew Hayes stepping in as Executive Director and Andrew Dornan moving to Executive Chair, alongside key technical appointments aimed at advancing its Independence Gold Project in Nevada.

Trigg Minerals has secured NSW Government approval for the transfer of its Achilles Project licence, enabling formal exploration of the high-grade Wild Cattle Creek antimony deposit.

GWR Group is actively pursuing a transformative transaction in Western Australia while maintaining a robust cash and investment position of $53.6 million. The company underscores its confidence in tungsten amid tightening global supply.

Whitebark Energy Limited has issued a supplementary bidder's statement updating its $3 million capital raising and correcting share valuation details in its ongoing takeover offer for King Energy Limited.

Carly Holdings Limited has agreed to merge its car subscription operations with Carbar Holdings in a $3.8 million deal, aiming to create a larger, more competitive player in Australia’s growing car subscription sector.

Citigroup Global Markets Australia has announced a fully franked AUD 0.30 dividend for its ORG CitiFirst Instalments, with key dates set for early March 2025.

Eumundi Group has officially been acquired by SEQ Hospitality Group, with shareholders receiving A$1.62 per share and significant board changes announced. The company is set to be delisted from the ASX imminently.

Avecho Biotechnology has responded to an ASX price query, confirming no undisclosed information exists to explain recent trading spikes, while highlighting market speculation linked to its Phase III CBD insomnia trial.

Laramide Resources Ltd. has acknowledged a delayed filing of a director's interest notice due to internal illness, prompting an ASX inquiry and procedural upgrades to prevent future lapses.